soluble programmed death-ligand 1

Overview

Soluble programmed death-ligand 1 (sPD-L1) is a circulating form of programmed death-ligand 1 (PD-L1), an immune checkpoint ligand that normally participates in the regulation of T-cell activity through the PD-1/PD-L1 axis. Unlike membrane-bound PD-L1, which is expressed on cells within tissues and tumors, the soluble form is detectable in body fluids such as serum and is studied as a potential biomarker of immune activation, immune suppression, and disease severity.

Biologically, sPD-L1 is of interest because it may reflect or contribute to systemic immune regulation in cancer and infectious disease. In oncology, PD-L1 expression is often linked to immune evasion and resistance to therapy, including immunochemotherapy and (chemo)radiotherapy. In infectious disease, circulating sPD-L1 has been investigated as a marker associated with inflammatory state and clinical severity. Recent studies have also examined strategies aimed at suppressing PD-L1 more broadly, including transcriptional silencing and degradation-based approaches, which provide context for understanding the relevance of soluble PD-L1 in immune escape.

Focus of Latest Publications

Recent publications have examined soluble programmed death-ligand 1 (sPD-L1) both as a biomarker and as part of broader PD-L1-targeted therapeutic strategies. In scrub typhus, a multicenter retrospective study measured serum cytokine and chemokine profiles at presentation and during follow-up, then validated findings in independent cohorts. Among the analytes tested, sPD-L1 showed a significant association with disease severity, trended lower during recovery, and outperformed conventional markers for identifying patients with organ dysfunction. Admission sPD-L1 also demonstrated very high discriminatory performance in validation cohorts, supporting its potential use for early risk stratification.

Several recent studies focused on mechanisms and interventions aimed at suppressing PD-L1 activity or expression in cancer. A programmable DNA hydrogel platform was designed to deliver polyvalent LYTAC mimics for extracellular PD-L1 degradation together with siSMARCAL1 to silence PD-L1 transcriptional activation, producing a dual “degrade-and-silence” effect in melanoma models. This approach reduced primary tumor growth, prevented postoperative recurrence, and elicited durable systemic antitumor immunity. In cervical cancer, the peptide UM-6 was reported to block PD-L1 N-glycosylation, disrupt its association with STT3A, promote ER retention and ERAD/proteasome-mediated degradation, and thereby reduce functional PD-L1 at the cell surface while enhancing cytotoxic T cell activity and limiting PD-1-associated T-cell exhaustion.

Other studies linked PD-L1 to therapy resistance and immune evasion in solid tumors. In cholangiocarcinoma, CALB2-driven signaling was shown to upregulate PD-L1 through a KRT7-mediated pathway, impairing T cell activation and contributing to chemoradiotherapy resistance; CALB2 silencing reduced PD-L1 expression and sensitized tumors to gemcitabine plus radiotherapy. In hepatocellular carcinoma, a bispecific small molecule scaffold was reported to inhibit both VEGFR2 and PD-L1, with the lead compound showing strong PD-L1 inhibition alongside antiproliferative and proapoptotic effects. In cold tumors, GPX1 knockout restored sensitivity to cuproptosis inducers and improved the efficacy of PD-L1 blockade, suggesting that metabolic resistance pathways can shape response to checkpoint inhibition.

Clinical data in advanced Kras-mutant lung adenocarcinoma further evaluated the relationship between PD-L1 expression and immunochemotherapy outcomes. In this retrospective cohort, first-line immunochemotherapy produced comparable efficacy across Kras subtypes, and PD-L1 tumor proportion score was not significantly associated with progression-free survival within the major Kras groups. Together, these publications portray sPD-L1 and PD-L1 as clinically and mechanistically important in infection and cancer, with emerging roles in risk stratification, immune evasion, and the design of multilevel PD-L1-suppressing therapies.

Key Publications

NEWJul GPX1 Drives Cuproptosis-Ferroptosis Resistance in Cold Tumors. (Free radical biology & medicine, 2026, PMID 42392283): "In vivo experiments confirmed that GPX1 knockout restored sensitivity to cuproptosis inducers and improved the efficacy of PD-L1 blockade."
NEWJun Programmable DNA hydrogels for dual-mode PD-L1 suppression via polyvalent LYTAC mimics and transcriptional silencing. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42258718): "...low response rates and acquired resistance-often driven by inadequate Programmed death-ligand 1 (PD-L1) suppression-remain significant barriers."
Jun Cytokine and chemokine profiles linked to early severity of scrub typhus: multicenter validation of soluble PD-L1. (Journal of clinical microbiology, 2026, PMID 42037422): "The serum soluble programmed death-ligand 1 (sPD-L1) levels differed significantly across severity groups (P = 0.04) and trended lower during recovery (P = 0.082)."
Jun H3K4 methylation of CALB2 facilitates immune evasion and chemoradiotherapy resistance in cholangiocarcinoma through KRT7-mediated PD-L1 upregulation. (International immunopharmacology, 2026, PMID 41936307): "Mechanistically, CALB2-activated NF-κB transcriptionally upregulated Keratin 7 (KRT7), which subsequently induced PD-L1 expression."
Mar UM-6 remodels the tumor immune microenvironment by blocking PD-L1 N-glycosylation and promoting ERAD-mediated degradation in cervical cancer. (Bioorganic chemistry, 2026, PMID 41916036): "Although PD-1/PD-L1 immune checkpoint blockade has expanded treatment options, durable responses are still limited."
Mar Design, synthesis, and mechanistic study of bispecific small molecules-based phenyl pyrazolopyrimidinone scaffold as dual-targeting VEGFR and PD-L1 immune checkpoint in hepatocellular carcinoma. (Bioorganic chemistry, 2026, PMID 41880789): "Mechanistically, 8g demonstrated strong inhibition of VEGFR2 (IC₅₀ = 0.38 μM), but it outperformed PD-L1 inhibition compared to Bavencio (IC₅₀ = 134.41 pg/mL and 217.74 pg/mL, respectively)."
Jun Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma. (International journal of cancer, 2026, PMID 41634944): "This study evaluated treatment efficacy across KRAS subtypes and examined the role of programmed death-ligand 1 (PD-L1) expression and co-mutations."